Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Nov 9:15:752420.
doi: 10.3389/fncir.2021.752420. eCollection 2021.

Dopamine Circuit Mechanisms of Addiction-Like Behaviors

Affiliations
Review

Dopamine Circuit Mechanisms of Addiction-Like Behaviors

Carli L Poisson et al. Front Neural Circuits. .

Abstract

Addiction is a complex disease that impacts millions of people around the world. Clinically, addiction is formalized as substance use disorder (SUD), with three primary symptom categories: exaggerated substance use, social or lifestyle impairment, and risky substance use. Considerable efforts have been made to model features of these criteria in non-human animal research subjects, for insight into the underlying neurobiological mechanisms. Here we review evidence from rodent models of SUD-inspired criteria, focusing on the role of the striatal dopamine system. We identify distinct mesostriatal and nigrostriatal dopamine circuit functions in behavioral outcomes that are relevant to addictions and SUDs. This work suggests that striatal dopamine is essential for not only positive symptom features of SUDs, such as elevated intake and craving, but also for impairments in decision making that underlie compulsive behavior, reduced sociality, and risk taking. Understanding the functional heterogeneity of the dopamine system and related networks can offer insight into this complex symptomatology and may lead to more targeted treatments.

Keywords: addiction; animal model; dopamine; mesostriatal; nigrostriatal; striatum; substance use disorder.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

FIGURE 1
FIGURE 1
Behavioral models used to classify phenotypes of substance use disorder. (Top) The behavioral criteria of SUDs (circled letters) can be sorted into three main categories: impaired control of substance use (Group I), impaired social behavior (Group II), and risky substance use (Group III). (Left) Common rodent experimental models and the SUD criteria they are thought to best approximate. Note that most models capture multiple SUD features. (Right) Mesostriatal circuits (light purple), including dopamine projections from the ventral tegmental area (VTA) to the nucleus accumbens (NAC), and nigrostriatal circuits (dark purple), including dopamine projections to the dorsomedial (DMS) and dorsolateral striatum (DLS), have generally dissociable roles in different components of major SUD models. In the middle panels, the most clearly defined roles for these two systems in each SUD category are listed.

References

    1. Aarts E., van Holstein M., Cools R. (2011). Striatal dopamine and the interface between motivation and cognition. Front. Psychol. 2:163. 10.3389/fpsyg.2011.00163 - DOI - PMC - PubMed
    1. Achterberg E. J. M., van Swieten M. M. H., Houwing D. J., Trezza V., Vanderschuren L. J. M. J. (2019). Opioid modulation of social play reward in juvenile rats. Neuropharmacology 159:107332. 10.1016/j.neuropharm.2018.09.007 - DOI - PubMed
    1. Ahmed S. H. (2018). Trying to make sense of rodents’ drug choice behavior. Prog. Neuropsychopharmacol. Biol. Psychiatry 87 3–10. - PubMed
    1. Ahmed S. H., Koob G. F. (1998). Transition from moderate to excessive drug intake: change in hedonic set point. Science 282 298–300. 10.1126/science.282.5387.298 - DOI - PubMed
    1. Ahmed S. H., Walker J. R., Koob G. F. (2000). Persistent increase in the motivation to take heroin in rats with a history of drug escalation. Neuropsychopharmacology 22 413–421. 10.1016/S0893-133X(99)00133-5 - DOI - PubMed

Publication types